{
  "id": 1760,
  "text": "Patients receiving cisplatin plus topotecan had statistically superior outcomes to those receiving cisplatin alone, with median OS of 9.4 and 6.5 months $[ \\mathrm { p } = 0 .0 1 7 ]$ , median PFS of 4.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Patients receiving cisplatin plus topotecan had statistically superior outcomes to those receiving cisplatin alone, with median OS of 9.4 and 6.5 months $[ \\mathrm { p } = 0 .0 1 7 ]$ , median PFS of 4.\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "联合使用顺铂和拓扑替康治疗晚期宫颈癌相比单独使用顺铂具有显著更优的临床结果表现。具体来说，联合治疗的患者中位总生存期（OS）为9.4个月，而单用顺铂的患者为6.5个月，表明联合方案改善了总生存期（统计学显著性 $p=0.017$）。此外，中位无进展生存期（PFS）也显示出联合治疗的优势。",
  "query": "根据提供的text，问题与宫颈癌是相关的，所以这里是一个符合条件的问题：\n\n在治疗晚期宫颈癌时，联合使用顺铂和拓扑替康与单独使用顺铂相比有什么不同的临床结果表现？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 根据提供的text，问题与宫颈癌是相关的，所以这里是一个符合条件的问题：\n\n在治疗晚期宫颈癌时，联合使用顺铂和拓扑替康与单独使用顺铂相比有什么不同的临床结果表现？\n\n<reference text>: Patients receiving cisplatin plus topotecan had statistically superior outcomes to those receiving cisplatin alone, with median OS of 9.4 and 6.5 months $[ \\mathrm { p } = 0 .0 1 7 ]$ , median PFS of 4.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "联合使用顺铂和拓扑替康治疗晚期宫颈癌相比单独使用顺铂具有显著更优的临床结果表现。具体来说，联合治疗的患者中位总生存期（OS）为9.4个月，而单用顺铂的患者为6.5个月，表明联合方案改善了总生存期（统计学显著性 $p=0.017$）。此外，中位无进展生存期（PFS）也显示出联合治疗的优势。"
}